Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of pemetrexed versus pemetrexed + carboplatin in pretreated advanced NSCLC
ISRCTN38269072Phase 2Completed
- Sponsor
- VU University Medical Centre (The Netherlands)
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by VU University Medical Centre (The Netherlands). Primary endpoint: Time to progression. Started Sep 2005; status: completed.
02
Drugs
pemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN38269072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38269072.